Randomization
Within 120 h of the new‐generation DES implantation, eligible patients will be randomized in a 1:1 ratio to receive either clopidogrel 75 mg daily or ticagrelor 90 mg twice daily in combination with dabigatran 110 mg twice daily for 12 months. The randomization will be done by the investigators through a central 24 h computerized randomization system of REDCap,